Nephros Statistics
Total Valuation
Nephros has a market cap or net worth of $23.09 million. The enterprise value is $20.62 million.
| Market Cap | 23.09M |
| Enterprise Value | 20.62M |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024, after market close.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Nephros has 10.54 million shares outstanding. The number of shares has increased by 0.86% in one year.
| Shares Outstanding | 10.54M |
| Shares Change (YoY) | +0.86% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 11.96% |
| Owned by Institutions (%) | 40.29% |
| Float | 5.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.62 |
| Forward PS | 1.36 |
| PB Ratio | 2.76 |
| P/FCF Ratio | 30.71 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 27.42 |
Financial Position
The company has a current ratio of 3.98, with a Debt / Equity ratio of 0.22.
| Current Ratio | 3.98 |
| Quick Ratio | 2.75 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.44 |
| Interest Coverage | -786.50 |
Financial Efficiency
Return on equity (ROE) is -18.20% and return on invested capital (ROIC) is -15.63%.
| Return on Equity (ROE) | -18.20% |
| Return on Assets (ROA) | -14.30% |
| Return on Capital (ROIC) | -15.63% |
| Revenue Per Employee | $459,290 |
| Profits Per Employee | -$50,806 |
| Employee Count | 31 |
| Asset Turnover | 1.29 |
| Inventory Turnover | 2.07 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +55.32% in the last 52 weeks. The beta is 1.27, so Nephros's price volatility has been higher than the market average.
| Beta (1Y) | 1.27 |
| 52-Week Price Change | +55.32% |
| 50-Day Moving Average | 2.57 |
| 200-Day Moving Average | 2.26 |
| Relative Strength Index (RSI) | 46.92 |
| Average Volume (30 Days) | 19,195 |
Short Selling Information
The latest short interest is 2,564, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 2,564 |
| Short Previous Month | 1,778 |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.05% |
| Short Ratio (days to cover) | 0.13 |
Income Statement
In the last 12 months, Nephros had revenue of $14.24 million and -$1.58 million in losses. Loss per share was -$0.15.
| Revenue | 14.24M |
| Gross Profit | 8.41M |
| Operating Income | -1.59M |
| Pretax Income | -1.58M |
| Net Income | -1.58M |
| EBITDA | -1.36M |
| EBIT | -1.57M |
| Loss Per Share | -$0.15 |
Balance Sheet
The company has $4.31 million in cash and $1.84 million in debt, giving a net cash position of $2.47 million or $0.23 per share.
| Cash & Cash Equivalents | 4.31M |
| Total Debt | 1.84M |
| Net Cash | 2.47M |
| Net Cash Per Share | $0.23 |
| Equity / Book Value | 8.36M |
| Book Value Per Share | 0.79 |
| Working Capital | 6.29M |
Cash Flow
In the last 12 months, operating cash flow was $827,000 and capital expenditures -$75,000, giving a free cash flow of $752,000.
| Operating Cash Flow | 827,000 |
| Capital Expenditures | -75,000 |
| Free Cash Flow | 752,000 |
| FCF Per Share | $0.07 |
Margins
Gross margin is 59.03%, with operating and profit margins of -11.19% and -11.06%.
| Gross Margin | 59.03% |
| Operating Margin | -11.19% |
| Pretax Margin | -11.06% |
| Profit Margin | -11.06% |
| EBITDA Margin | -9.54% |
| EBIT Margin | -11.05% |
| FCF Margin | 5.28% |
Dividends & Yields
Nephros does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.86% |
| Shareholder Yield | -0.86% |
| Earnings Yield | -6.82% |
| FCF Yield | 3.26% |
Analyst Forecast
The average price target for Nephros is $5.00, which is 128.31% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.00 |
| Price Target Difference | 128.31% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 10, 2019. It was a reverse split with a ratio of 1:9.
| Last Split Date | Jul 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
Nephros has an Altman Z-Score of -11.69 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.69 |
| Piotroski F-Score | 4 |